Find Out If You Have a Case

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Dupixent Lawsuit — Free, Confidential Case Review

Treated for “eczema” that turned out to be lymphoma?

CTCL is often mistaken for eczema for years. If Dupixent came before the real diagnosis, that timeline matters — and it is worth two confidential minutes.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.

Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?

Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →

No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Or talk to a person now: (888) 348-2735 — answered 24/7

Stefanie A. Murphy & Matthew T. Marin

Partners

Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.

Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.

This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.

Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.

Why is CTCL so often mistaken for eczema?

The claims consolidated in the Dupixent lawsuit sit on top of a medical reality that has nothing to do with courtrooms: in its early patch stage, mycosis fungoides — the most common form of CTCL — produces itchy, scaly, red or discolored patches that look and feel like the dermatitis millions of people live with. The patches can even respond, partly and temporarily, to the same topical steroids used for eczema, which makes the resemblance more convincing rather than less.

Physicians describe early CTCL as a diagnosis of exclusion: it is often confirmed only after other explanations have failed, sometimes across years of visits. Early biopsies frequently come back inconclusive or “atypical,” because the malignant cells can be sparse and scattered in early disease. A 2026 editorial in the American Journal of Clinical Dermatology puts it plainly, noting the “considerable clinical and histopathologic overlap between AD and early-stage MF, which may lead to initial misdiagnosis.” That is the medical literature talking — not a law firm.

How long do misdiagnosis journeys really last?

Accounts documented in the patient community and in published case reports follow a consistent pattern. Some people are told for eighteen months that a stubborn patch is “some weird sort of eczema or psoriasis.” Others carry an eczema diagnosis for five years, ten years, or — in documented accounts — more than two decades before a biopsy finally names the disease. Along the way they typically see several doctors, cycle through steroid treatments, and often have two or three biopsies come back inconclusive before one finds the answer.

The detail that recurs in these histories is not “my eczema got worse.” It is more specific: one area stopped behaving like the rest. A patch that never healed. A spot that ignored steroids that worked everywhere else. A lesion that kept returning to the same place. People who have lived with eczema for decades tend to write every new flare off as more of the same — because for their whole lives, it always was.

Could you have caught it sooner?

Almost certainly not — and it is worth saying directly, because so many people quietly blame themselves. If board-trained dermatologists, looking at the skin and at biopsy slides, routinely need years and repeated tests to distinguish early CTCL from eczema, then a patient who assumed a familiar-looking rash was the same disease they had managed since childhood was being reasonable, not careless.

The same grace extends to your doctor. Treating persistent, itchy, scaly patches as severe atopic dermatitis is exactly what the presentation suggested, and your dermatologist was working without any lymphoma warning on the label of the drug being prescribed — Dupixent’s FDA label contains no lymphoma or malignancy warning to this day. The allegation in this litigation is that the manufacturers, not the treating physicians, had the emerging safety information and failed to pass it on. You couldn’t have known. Often, neither could your doctor.

If it may have been lymphoma all along, doesn’t that defeat the lawsuit?

This is the honest, contested center of the science, and you should hear a straight version of it. Researchers studying the reported association between dupilumab and CTCL describe two competing explanations. One is that the drug plays a role in the development or acceleration of the disease. The other is called protopathic bias, or “unmasking”: some people who developed CTCL on Dupixent may have had undetected lymphoma the whole time — misdiagnosed as the very eczema the drug was prescribed to treat — so the diagnosis after starting the drug reflects discovery, not causation. The published studies report a statistical association while their own authors flag both possibilities; no study proves causation, and this website will not tell you otherwise.

Here is why the unmasking debate does not simply end the legal question. First, which explanation fits an individual person is a records question — which is exactly why cases begin with a records review rather than a conclusion. Second, plaintiffs’ central allegation is failure to warn: they allege that as reports and studies accumulated, the manufacturers should have warned patients and physicians, and that a warning would have prompted earlier biopsies and earlier diagnoses. On that theory, plaintiffs allege, a delayed diagnosis is not a defense to the claim — it is part of the harm. No court has ruled on any of these allegations, and the litigation will test the evidence on both sides.

What does your misdiagnosis history mean for a claim?

Practically, the years you spent being treated for eczema are not an embarrassment to explain away — they are the documentary spine of a potential case. Records of dermatology visits, steroid and other prescriptions, biopsy reports (including the inconclusive ones), Dupixent start and stop dates, and the eventual CTCL diagnosis together establish the timeline everything else depends on. The basic screening questions — a CTCL or qualifying T-cell lymphoma diagnosis during or after Dupixent use, with no minimum length of use required — are laid out on our do I qualify page, and families of people who have passed away can pursue claims through an estate.

What should you do next?

Keep every medical question where it belongs: with your doctor. Nothing about a legal claim requires changing your medication or second-guessing your care, and if you have concerns about a patch, a symptom, or Dupixent itself, your prescriber and dermatologist are the right people to ask — a law firm is not.

On the legal side, a case review is free, confidential, and carries no obligation. It is mostly a records conversation: what you were diagnosed with and when, what you took, and what your state’s law requires. Legal deadlines vary by state and can turn on your specific dates, so a review is the only reliable way to learn how they apply to you.

What else do people ask about eczema misdiagnosis and CTCL?